BSE filing, NSE: HESTERBIO. Summary written from the filing by ALFA Finder's alert engine.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,232.00
- Market cap
- ₹1,899 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.9×Sector 46.5×
- Promoter holding
- 44.28%-9.45% QoQ
- FII holding
- 0.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Board Meeting Date
Hester Biosciences scheduled its Board of Directors meeting for 5 November 2026 to review unaudited H1 FY27 results. No decisions or figures are reported yet.
Hester Biosciences Management Change
Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.
Hester Biosciences Capacity Expansion: ₹1.05 Cr Investment
Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.
- Value
- ₹1.05 Cr
- Execution
- six months
Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.